Dermira Inc (NASDAQ:DERM) Director David E. Cohen sold 600 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $25.49, for a total transaction of $15,294.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Dermira Inc (NASDAQ:DERM) remained flat at $$24.21 during midday trading on Tuesday. The company’s stock had a trading volume of 303,751 shares, compared to its average volume of 425,743. The company has a quick ratio of 4.68, a current ratio of 4.68 and a debt-to-equity ratio of 1.40. Dermira Inc has a one year low of $21.35 and a one year high of $38.75.

A number of research analysts recently issued reports on the stock. Leerink Swann reiterated an “outperform” rating and issued a $41.00 target price (down from $47.00) on shares of Dermira in a research note on Tuesday, November 7th. BidaskClub upgraded shares of Dermira from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 16th. Mizuho reiterated a “buy” rating and issued a $43.00 target price (up from $40.00) on shares of Dermira in a research note on Thursday, September 7th. Zacks Investment Research upgraded shares of Dermira from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $43.00 target price (down from $46.00) on shares of Dermira in a research note on Tuesday, November 7th. Four equities research analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $43.33.

A number of hedge funds and other institutional investors have recently bought and sold shares of DERM. BNP Paribas Arbitrage SA grew its position in Dermira by 2,220.7% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 3,975 shares during the last quarter. Quantbot Technologies LP grew its position in Dermira by 75.4% in the 3rd quarter. Quantbot Technologies LP now owns 5,371 shares of the biopharmaceutical company’s stock worth $145,000 after purchasing an additional 2,309 shares during the last quarter. SG Americas Securities LLC grew its position in Dermira by 66.8% in the 2nd quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 2,203 shares during the last quarter. Legal & General Group Plc grew its position in Dermira by 16.3% in the 1st quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock worth $236,000 after purchasing an additional 963 shares during the last quarter. Finally, Ardsley Advisory Partners acquired a new stake in Dermira in the 2nd quarter worth $291,000. Institutional investors own 99.54% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Dermira Inc (DERM) Director Sells 600 Shares of Stock” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/12/05/insider-selling-dermira-inc-derm-director-sells-600-shares-of-stock.html.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Insider Buying and Selling by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc and related companies with MarketBeat.com's FREE daily email newsletter.